|[March 20, 2017]
REVOLUTION Medicines Appoints Cancer Leader Dr. Stephen Kelsey as President of Research and Development
Medicines, Inc., a company focused on frontier cancer targets and
drug discovery inspired by nature's lessons, today announced the
appointment of Stephen (Steve) Kelsey, M.D., an accomplished
physician-scientist, oncologist and cancer drug developer, as president
of research and development.
"We are proud and excited to have Dr. Kelsey join as a senior leader of
our company," said Mark A. Goldsmith, M.D., Ph.D., president and chief
executive officer of REVOLUTION Medicines. "Steve has had a
distinguished career in oncology as both an academic clinician and a
drug development executive in the biotechnology industry. He is superbly
positioned to help us deliver great benefit to cancer patients by
advancing our lead programs and creating a sustainable product pipeline
that harnesses frontier oncology targets."
Dr. Kelsey has extensive industry experience in oncology discovery and
development. Most recently, he served as president of Onkaido
Therapeutics, a Moderna Venture focused on oncology mRNA therapeutics.
Prior to Onkaido, he served in senior positions at Medivation and Geron,
where he led efforts to develop therapeutics to fight cancer. Prior to
Geron, he served as vice president of hematology/oncology at Genentech,
whre he built the exploratory clinical development group and played a
significant role in the development of key products Perjeta®, Kadcyla®
and Erivedge®. He began his career in life sciences at Pharmacia/SUGEN
where he led the initial clinical development and clinical
proof-of-concept for sunitinib (Sutent®) in GIST tumors, resulting in
its approval after the acquisition by Pfizer. Before his transition to
industry, Dr. Kelsey was a senior lecturer in Haematology/Oncology at
St. Bartholomews and the Royal London School of Medicine and Dentistry.
He was also director of the haematology/oncology phase I/II clinical
trials unit at Barts and the London School of Medicine and Dentistry and
head of the Bone Marrow Transplant unit.
Dr. Kelsey holds bachelor of medicine and bachelor of surgery degrees
(MB ChB), as well as a doctorate of medicine (M.D.) degree from the
University of Birmingham, U.K. and is a fellow of the Royal College of
Physicians (FRCP) of London and the Royal College of Pathologists
"REVOLUTION Medicines uses a novel approach to drug discovery that
enables it to tackle promising cancer targets that have been difficult
to access by conventional means," said Dr. Kelsey. "I'm impressed with
the quality of the company's research team, founders and advisors, and
am keen to help bring the next generation of transformational
therapeutics to cancer patients."
About REVOLUTION Medicines
The mission of REVOLUTION Medicines is to discover and develop new drugs
directed toward frontier oncology targets for cancer patients. The
company draws inspiration from nature's lessons including natural
products that are inherently rich with biological function. REVOLUTION
Medicines deploys an innovative toolkit including REVBLOCKS®, an
integrated suite of modular synthesis methodologies applied to simple
chemical "building blocks," and the REVEAL® computational platform,
which uses evolution's lessons to inform selection of chemical scaffolds
and guide drug design for non-classical drug targets. Headquartered in
Redwood City, Calif. at the intersection of Silicon Valley and the
birthplace of biotechnology, REVOLUTION Medicines is a private company
financed by top-tier investors Third Rock Ventures and The Column Group.
For more information, please visit www.revolutionmedicines.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170320005612/en/
[ Back To TMCnet.com's Homepage ]